Novel combination therapy with imiquimod and tyrosine kinase inhibitor against renal cell carcinoma
| Project/Area Number |
15K10593
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kochi University |
|---|
Principal Investigator |
KARASHIMA Takashi 高知大学, 教育研究部医療学系臨床医学部門, 准教授 (60304672)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
執印 太郎 高知大学, その他部局等, その他(教授相当) (70128601)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KURODA Naoto 高知大学, その他の部局等, 客員教授 (60291457)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Keywords | 腎癌 / 免疫療法 / チロシンキナーゼ阻害剤 / 腎がん / イミキモド |
|---|
| Outline of Final Research Achievements |
The specific aim of the study is to demonstrate a novel therapeutic strategy that can be applied clinically to a combination therapy with transdermal administration of Imiquimod as an immunoagent via Toll-like receptor 7 and oral administration of a tyrosine kinase inhibitor to in renal cell carcinoma. The combination therapy showed a synergistic antitumor effect by activating tumor-specific cytotoxic T cells and inducing it in to the tumor. An appropriate tyrosine kinase inhibitor for combination therapy with imiquimod was sorafenib. Relatively low dose sorafenib was effective. In addition, the combination therapy was safety in animal models.
|
Report
(4 results)
Research Products
(4 results)
